The global prefilled syringes market is expanding as the biologics pipeline exceeds 8,000 active clinical-stage molecules requiring cold-chain-compatible single-dose drug delivery formats, and GLP-1 receptor agonist prescriptions surge globally.

The market was valued at approximately USD 10.42 billion in 2025 and is projected to reach roughly USD 29.68 billion by 2035, growing at a CAGR of approximately 11.72%. Growth is supported by biologics pipeline expansion, GLP-1 / obesity drug uptake, needlestick safety regulations, home healthcare shift, vaccine preparedness programs, polymer barrel material innovation, and connected-device telemetry integration.marketresearchfuture

As of 2025, there were over 8,200 active compounds in the worldwide biologics pipeline, with 62% of Phase III candidates being monoclonal antibodies and fusion proteins. Each licensed biologic usually needs a ready-to-use injectable device format to preserve protein stability during storage and administration.

Semaglutide and tirzepatide prescriptions exceeded 45 million annualized scripts in the U.S. by Q4 2024, a 67% year-over-year increase. Both drugs ship predominantly in autoinjector pen systems, and this single therapeutic class now represents an estimated 12% of global prefilled syringe demand.

Diabetes accounted for roughly 37% of prefilled syringe shipments in 2025, reflecting the global insulin pen installed base exceeding 300 million units. Vaccines represent the fastest-expanding application at a 14.58% CAGR, propelled by pandemic-preparedness stockpiling and WHO prequalification of single-dose drug delivery formats.

Key players include BD (Becton, Dickinson), Gerresheimer AG, Schott AG, West Pharmaceutical Services, Stevanato Group, Nipro Corporation, Baxter International, and Terumo Corporation.

Read more: Prefilled Syringes Market Size, Trends

People Also Ask

Q1. What is driving the prefilled syringes market?
Biologics pipeline expansion, GLP-1 drug uptake, needlestick safety regulations, home healthcare shift, and vaccine preparedness programs are major drivers.

Q2. Which application is growing fastest?
Vaccines are the fastest-expanding application at a 14.58% CAGR through 2035.

Tags: prefilled syringes, biologics, GLP-1 drugs, autoinjector pens, single-dose drug delivery